Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Thymulin Dosage Protocol - Peptide Dosages

Thymulin (5 mg) Dosage Protocol A zinc-dependent thymic nonapeptide (formerly “serum thymic factor”/FTS), studied since the 1970s in T-cell immunology. Research-use-only — not an approved medicine and not the same molecule as Thymalin. This page is an educatio

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Thymulin (5 mg) Dosage Protocol

A zinc-dependent thymic nonapeptide (formerly “serum thymic factor”/FTS), studied since the 1970s in T-cell immunology. Research-use-only — not an approved medicine and not the same molecule as Thymalin. This page is an educational reference, not a dosing recommendation.

Why Thymulin draws research interest

These are the directions researchers and the peptide community most often explore Thymulin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

Zinc is part of the molecule, not a cofactor you add later

What makes thymulin unusual is that its biological activity is strictly zinc-dependent. Binding studies show the nonapeptide binds a single zinc ion with sub-micromolar affinity, and NMR and antibody work show the zinc gives the peptide a specific folded conformation that zinc-free thymulin does not have. Remove the zinc and you have the same amino-acid sequence with none of the activity. This is why the peptide is described as a zinc-metallopeptide rather than simply "a peptide that works better with zinc."

Thymulin is a defined molecule; Thymalin is a mixture

This is the single most important thing to understand before reading anything about "thymic peptides." Thymulin is one chemically defined nonapeptide with a known sequence. Thymalin is a crude polypeptide extract prepared from thymus tissue — an undefined mixture of many peptides. They are not interchangeable, they do not have the same evidence base, and a vendor using the two names loosely is not describing the same product. Our separate Thymalin page covers the extract; this page covers the defined peptide.

A genuine, well-documented human link: zinc status

One part of the thymulin story is unusually well grounded in human data. In carefully controlled studies of mild zinc deficiency, serum thymulin activity fell and then recovered when subjects were given zinc — making thymulin activity a sensitive readout of zinc status and tying thymic hormone function to a common nutritional variable. That is a real, reproducible finding about the endogenous hormone. It is not the same as evidence that injecting a research vial of synthetic thymulin produces a health benefit, and the honest reading keeps those two ideas separate.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

Mix & measure Thymulin · 5 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

A zinc-bound thymic nonapeptide that promotes T-lymphocyte differentiation and modulates T-cell subset functions. The zinc ion is not optional: without it the peptide loses its characteristic three-dimensional conformation and its biological activity.

A laboratory research peptide, not a drug. It is not approved for human use, has no established dose, and is distinct from the crude thymus extract sold as "Thymalin". The wellness/anti-aging claims attached to research vials are not backed by modern controlled human trials.

The solid science is decades-old immunology: thymulin induces T-cell markers, its serum level falls in human zinc deficiency and rises again with zinc repletion, and it declines with age as the thymus involutes. Therapeutic benefit in humans was never established.

Quickstart Highlights

Thymulin is a zinc-dependent nonapeptide hormone produced by the epithelial cells of the thymus — sequence pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn. It was first characterized in the 1970s as the “facteur thymique sérique” (serum thymic factor, FTS) by Jean-François Bach and Mireille Dardenne at Hôpital Necker in Paris, and later renamed thymulin once it was recognized that the peptide is biologically active only when it is coupled to a zinc ion[1][2].

This page is an educational reference on what thymulin is, what the research literature actually shows, and how a lyophilized research vial is reconstituted to a known concentration. It is not medical advice and not a protocol to administer the peptide. Thymulin is not approved by the FDA or any regulator as a therapeutic. One point matters up front: thymulin is not the same product as “Thymalin.” Thymulin is a single, chemically defined zinc-bound nonapeptide, whereas Thymalin is a crude polypeptide extract of thymus tissue — a mixture, not a molecule. They are routinely confused because the names look alike; this reference is about the defined peptide.

A thymic nonapeptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) from thymic epithelial cells whose activity requires a bound zinc ion[1][3]. Formerly called serum thymic factor (FTS).

2 mL bacteriostatic water per 5 mg vial → 2.5 mg/mL. This is a lab-handling reference only; the site provides no dose for administration.

Not FDA-approved for any use. Studied for decades as an experimental immunoregulator, but never developed into an approved drug. No validated human protocol exists.

Historical immunology + animal research. Its T-cell-differentiating activity, zinc dependence and age-related decline are well documented[1][4]; there are no modern controlled human efficacy trials supporting the wellness claims made for grey-market vials.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01VK2735 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. VK2735 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02P21 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. P21 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03Pemvidutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Pemvidutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04Ecnoglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Ecnoglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Cortexin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Cortexin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
comparison

Pulse versus plateau: the same hormone can build or destroy bone

What makes PTH biology fascinating is that the effect flips depending on how the hormone is delivered. A brief once-daily spike of PTH(1–34) tips the balance toward osteoblasts and net bone…

Source: dosagepeptide.com
Research context

Read sources and limitations before applying a claim.

Why Triptorelin draws research interest

These are the directions researchers and the peptide community most often explore Triptorelin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

Source: dosagepeptide.com ↗

What the Evidence Actually Shows, and at What Level of Confidence

Separating mechanism from proof is the single most important discipline in reading this literature. The mechanistic case is strong and internally consistent. The clinical case is early, small, and deliberately modest in what it claims. Here it is worth being explicit about the hierarchy of evidence, from weakest to strongest: cell-culture experiments, animal models, uncontrolled human observations, small randomized safety trials, and finally large randomized efficacy trials with disease-relevant endpoints. NAD+ in Parkinson’s disease currently has a great deal at the lower rungs and very little at the top.1 At the preclinical level, NAD+ precursors have shown protective effects across multiple Parkinson’s models. Boosting NAD+ has improved mitochondrial function, reduced alpha-synuclein toxicity, and extended survival in fruit-fly and rodent systems, and the 2025 UPRmt/mitophagy work provided a specific mechanistic account of one way this protection might occur.1,5,6 These are meaningful signals, but animal models of Parkinson’s disease are notoriously imperfect predictors of human benefit; the graveyard of neuroprotective agents that worked in mice and failed in people is large. Preclinical success is a reason to run a human trial, not a substitute for one. The most important human data come from a small set of Norwegian trials. The NADPARK study, published in Cell Metabolism in 2022, was a randomized, double-blind, placebo-controlled phase I trial in 30 newly diagnosed, treatment-naive patients who received 1,000 mg of oral nicotinamide riboside or placebo for 30 days.1 Its purpose was to establish safety and target engagement. It succeeded on both counts: NR was well tolerated and produced a significant, though variable, increase in cerebral NAD+ measured by phosphorus magnetic resonance spectroscopy, alongside changes in related metabolites in cerebrospinal fluid. In the subgroup whose brain NAD+ actually rose (the responders), the investigators observed altered cerebral metabolism on FDG-PET and reported an associated mild clinical improvement, and blood and muscle transcriptomics showed upregulation of mitochondrial, lysosomal, and proteasomal gene programs.1 These are encouraging exploratory findings. They are not proof of efficacy: the trial was not powered or designed to demonstrate a change in disease progression, the clinical signal was in a post-hoc responder subgroup, and 30 days is a fraction of the timescale over which Parkinson’s disease evolves. The follow-up NR-SAFE trial, published in Nature Communications in 2023, tested a much higher dose, 3,000 mg of NR daily (1,500 mg twice daily), against placebo for four weeks in 20 patients, again primarily to assess safety.2 All 20 participants completed the study. There were 42 adverse events in total, 25 in the NR group and 17 in the placebo group, and critically all were graded mild, with no moderate or severe events and no statistically significant difference in adverse-event frequency between arms. No painful flushing was reported. The NR group showed a statistically significant improvement in total MDS-UPDRS score (from 51.0 to 40.3, p = 0.007) while placebo did not, but the authors themselves flagged this as preliminary and potentially confounded, including by differences in the timing of levodopa dosing relative to assessment.2 A responsible reading treats NR-SAFE as reassuring on high-dose safety and hypothesis-generating on efficacy, nothing more. The decisive test is the NOPARK study (NCT03568968), a phase III randomized, double-blind, placebo-controlled trial of 1,000 mg oral NR daily over 52 weeks in roughly 400 patients with early Parkinson’s disease across multiple Norwegian centers, with the change in total MDS-UPDRS as its primary endpoint.3 This is the appropriately sized, appropriately long, efficacy-focused trial the field needs. As of this writing the trial has completed enrollment and follow-up, but its primary clinical results have not been published, so no conclusion about efficacy can be drawn. Until those results appear, the honest evidence level for “NAD+ precursors slow Parkinson’s progression” is: plausible mechanism, safe in the short term at the doses tested, and unproven in humans. Alongside these interventional data sit epidemiological signals that are hypothesis-supporting but causally weak, discussed in the next section.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How To Take

▪Swallow whole: take the capsule(s) with water, before a meal, once daily unless a specific product directs otherwise. ▪Keep to the course: take it consistently for the course length, then stop — the convention is a short course, not continuous use. ▪Do not over-stack: avoid combining many organ bioregulators; there is no controlled evidence for combinations.

Source: dosagepeptide.com ↗
Dosage reference

GHRP-6 (2mg Vial) Dosage Protocol

Ghrelin-receptor GH secretagogue (appetite-stimulating) — research/educational dosing reference.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →